T-1301 is under clinical development by Taivex Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how T-1301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
T-1301 is under development for the treatment of acute myeloid leukemia (AML), gastrointestinal stromal tumors (GISTs), advanced solid tumors, and lymphoma. The therapeutic candidate is administered through oral route in form of capsule. It acts by targeting multiple kinases including KIT and FLT-3.
Taivex Therapeutics overview
Taivex Therapeutics, is a proprietary technology platform that required for appropriate mitotic progression and chromosomal segregation. The company is headquartered in Taipei, Taiwan.
For a complete picture of T-1301’s drug-specific PTSR and LoA scores, buy the report here.